The Top 5 Biosimilars Articles for the Week of February 12

February 16, 2018

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 12, 2018.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 12.

Number 5: On the same day that the President released his budget proposal that called for $2 billion less in funding for the National Institutes of Health than allocated by Congress, a new paper argued that a reduction in funding would significantly delay the emergence of new drugs.

Number 4: Roche has released phase 2 data for a novel drug that could compete with biosimilars of anti-vascular endothelial growth factor therapies.

Number 3: The White House’s Council of Economic Advisors said in a new white paper that the FDA should finalize biosimilar interchangeability guidelines that are easy and inexpensive to adhere to in order to promote competition.

Number 2: South Dakota became the latest state to pass legislation governing the substitution of interchangeable biosimilars for their reference products.

Number 1: Celltrion has received authorization to market its biosimilar trastuzumab, Herzuma, in the European Union.

Also this week, attorneys George Yu and Christopher Bruno, both of Schiff Hardin, explained how the Supreme Court’s eventual decision in the ongoing Oil States case could affect the biologics industry.

Finally, last week, our e-newsletter asked whether the United States should follow Australia’s lead by not using 4-letter suffixes in the names of biosimilars and biologics.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.